Header Logo

Connection

Sunita Nathan to Hematopoietic Stem Cell Transplantation

Back to Details
This is a "connection" page, showing publications Sunita Nathan has written about Hematopoietic Stem Cell Transplantation.
Sunita Nathan
Connection Strength
10.633
Hematopoietic Stem Cell Transplantation
  1. Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2020 08; 61(8):2008-2011.
    View in: PubMed
    Score: 0.607
  2. DLBCL After Allogeneic HCT in a Patient With Transformed DLBCL: Does It Matter Whether Relapse or PTLD? Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):264-266.
    View in: PubMed
    Score: 0.594
  3. Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. Bone Marrow Transplant. 2020 04; 55(4):833-835.
    View in: PubMed
    Score: 0.578
  4. Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies. Infect Dis Clin North Am. 2019 06; 33(2):331-359.
    View in: PubMed
    Score: 0.564
  5. Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score. J Am Heart Assoc. 2024 Jan 02; 13(1):e033599.
    View in: PubMed
    Score: 0.196
  6. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024 Jan; 59(1):76-84.
    View in: PubMed
    Score: 0.194
  7. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Transplant Cell Ther. 2024 Jan; 30(1):114.e1-114.e16.
    View in: PubMed
    Score: 0.193
  8. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. Blood Adv. 2023 08 08; 7(15):3993-4002.
    View in: PubMed
    Score: 0.191
  9. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 09; 29(9):548-555.
    View in: PubMed
    Score: 0.190
  10. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul 01; 108(7):1900-1908.
    View in: PubMed
    Score: 0.190
  11. Scedosporium infection disseminated "from toe to head" in allogeneic stem cell transplant recipient: a case report. BMC Infect Dis. 2023 May 25; 23(1):353.
    View in: PubMed
    Score: 0.188
  12. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. Am J Hematol. 2023 04; 98(4):608-619.
    View in: PubMed
    Score: 0.184
  13. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023 01 01; 108(1):150-160.
    View in: PubMed
    Score: 0.183
  14. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia. 2023 05; 37(5):1006-1017.
    View in: PubMed
    Score: 0.181
  15. Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 10; 57(10):1632-1634.
    View in: PubMed
    Score: 0.178
  16. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 07 12; 6(13):3991-3995.
    View in: PubMed
    Score: 0.177
  17. Transplantation provides superior survival high risk myeloid malignancies in older patients. Leuk Lymphoma. 2022 10; 63(10):2494-2498.
    View in: PubMed
    Score: 0.175
  18. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2022 07; 57(7):1150-1163.
    View in: PubMed
    Score: 0.175
  19. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
    View in: PubMed
    Score: 0.173
  20. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022 01 11; 6(1):339-357.
    View in: PubMed
    Score: 0.171
  21. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022 01 08; 6(3):828-847.
    View in: PubMed
    Score: 0.171
  22. Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplant Cell Ther. 2022 06; 28(6):335.e1-335.e17.
    View in: PubMed
    Score: 0.169
  23. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant. 2022 01; 57(1):31-37.
    View in: PubMed
    Score: 0.168
  24. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021 09 28; 5(18):3528-3539.
    View in: PubMed
    Score: 0.168
  25. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 2021 12; 56(12):3068-3077.
    View in: PubMed
    Score: 0.168
  26. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2021 08 01; 106(8):2295-2296.
    View in: PubMed
    Score: 0.166
  27. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 06 10; 137(23):3291-3305.
    View in: PubMed
    Score: 0.164
  28. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplant Cell Ther. 2021 08; 27(8):679.e1-679.e8.
    View in: PubMed
    Score: 0.163
  29. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 09; 56(9):2108-2117.
    View in: PubMed
    Score: 0.163
  30. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659.
    View in: PubMed
    Score: 0.162
  31. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683.
    View in: PubMed
    Score: 0.161
  32. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplant Cell Ther. 2021 01; 27(1):68.e1-68.e9.
    View in: PubMed
    Score: 0.157
  33. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia. 2020 10; 34(10):2809-2812.
    View in: PubMed
    Score: 0.155
  34. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2020 11; 26(11):2139-2146.
    View in: PubMed
    Score: 0.155
  35. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 07 14; 4(13):3180-3190.
    View in: PubMed
    Score: 0.154
  36. Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Adv. 2020 05 26; 4(10):2317-2324.
    View in: PubMed
    Score: 0.153
  37. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 10; 191(1):44-51.
    View in: PubMed
    Score: 0.153
  38. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020 05 12; 4(9):1965-1973.
    View in: PubMed
    Score: 0.153
  39. Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020 Dec; 26(8):2047-2051.
    View in: PubMed
    Score: 0.152
  40. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020 08; 190(4):573-582.
    View in: PubMed
    Score: 0.152
  41. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020 03 24; 4(6):983-992.
    View in: PubMed
    Score: 0.151
  42. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biol Blood Marrow Transplant. 2020 06; 26(6):1137-1143.
    View in: PubMed
    Score: 0.150
  43. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 05 15; 126(10):2279-2287.
    View in: PubMed
    Score: 0.150
  44. Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97.
    View in: PubMed
    Score: 0.148
  45. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 01 15; 126(2):293-303.
    View in: PubMed
    Score: 0.146
  46. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2020 05; 105(5):1329-1338.
    View in: PubMed
    Score: 0.146
  47. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 06 25; 3(12):1826-1836.
    View in: PubMed
    Score: 0.143
  48. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 05; 54(5):648-661.
    View in: PubMed
    Score: 0.140
  49. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6.
    View in: PubMed
    Score: 0.139
  50. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 05; 54(5):662-673.
    View in: PubMed
    Score: 0.138
  51. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 05; 25(5):e145-e154.
    View in: PubMed
    Score: 0.138
  52. Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):e46-e54.
    View in: PubMed
    Score: 0.138
  53. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
    View in: PubMed
    Score: 0.137
  54. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant. 2018 03; 24(3):486-493.
    View in: PubMed
    Score: 0.129
  55. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 07; 174(2):235-48.
    View in: PubMed
    Score: 0.114
  56. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.